Myriad RBM, Sanofi Partner on Biomarkers for Diabetes | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market on Monday that its wholly owned subsidiary Myriad RBM has entered into a diabetes biomarker collaboration with Sanofi and Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.